Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials

REFERENCES

• PaleIla FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27–34.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Neaton J, Lundgren JD. The role of HIV in seri-ous diseases other than AIDS. AIDS. 2008;22:2409–2418.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1,2009; 1–161. http://www.aidsinfo.nih.gov/ContentFiles/AduItand-AdolescentGL.pdf.
   Google Scholar
• Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society--USA Panel. JAMA. 2010;304:321–333.
   PubMed Web of Science ®Google Scholar
• Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007;44:179–187.
   PubMed Web of Science ®Google Scholar
• Mann B, Thiebaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 2009;23:1743–1753.
   PubMed Web of Science ®Google Scholar
• CASCADE Collaboration. Effective therapy has altered the spectrum of cause-specific mortality following HIV sero-conversion. AIDS. 2006;20:741–749.
   PubMed Web of Science ®Google Scholar
• Pacheco AG, Tuboi SH, Faulhaber JC, Harrison LH, Schechter M. Increase in non-AIDS related conditions as causes of death among HIV-infected individuals in the HAART era in Brazil. PLoS One. 2008;3:e1531.
   PubMed Web of Science ®Google Scholar
• The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS. 2010;24:1537–1548.
   PubMed Web of Science ®Google Scholar
• The Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretro-viral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387–1396.
   PubMed Web of Science ®Google Scholar
• The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.
   PubMed Web of Science ®Google Scholar
• The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiret-roviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133–1144.
   PubMed Web of Science ®Google Scholar
• Currier JS. Update on cardiovascular complications in HIV infection. Top HIV Med. 2009;17:98–103
   PubMedGoogle Scholar
• Baker JV, Henry WK, Neaton JD. The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS. 2009;4:176–182.
   PubMed Web of Science ®Google Scholar
• Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007;21: 2445–2453.
   PubMed Web of Science ®Google Scholar
• Worm SW, De Wit S, Weber R, et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subse-quent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collec-tion on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation. 2009;119:805–811.
   PubMed Web of Science ®Google Scholar
• Florescu D, Kotler DP. Insulin resistance, glucose intoler-ance and diabetes mellitus in HIV-infected patients. Antivir Ther 2007;12:149–162.
   PubMed Web of Science ®Google Scholar
• Saber AA, Aboolian A, LaRaja RD, Baron H, Hanna K. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg. 2001;67: 645–647.
   PubMed Web of Science ®Google Scholar
• Levine AM, Vigen C, Gravink J, Mack W, Watts CH, Lieb-man HA. Progressive prothrombotic state in women with advancing HIV disease. J Acquir Immune Defic Syndr. 2006;42:572–577.
   PubMed Web of Science ®Google Scholar
• Jong E, Louw S, Meijers JCM, et al. The hemostatic bal-ance in HIV-infected patients with and without antiretroviral therapy: Partial restoration with antiretroviral therapy. AIDS Patient Care STDS. 2009;23:1001–1007.
   PubMed Web of Science ®Google Scholar
• Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malig-nancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 2009;52:203–208.
   PubMed Web of Science ®Google Scholar
• Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected indi-viduals. J Acquir Immune Defic Syndr 2009;52:611–622.
   PubMed Web of Science ®Google Scholar
• Palefsky J. Human papillomavirus-related tumors in HIV. Curr Opin OncoL 2006;18:463–468.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS. 2009;4:3–10.
   PubMed Web of Science ®Google Scholar
• Hu J, Ludgate L. HIV-HBV and HIV-HCV coinfection and liver cancer development. Cancer Treat Res. 2007;133:241–252.
   PubMedGoogle Scholar
• Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associ-ated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45:103–110.
   PubMed Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22:1979–1991.
   PubMed Web of Science ®Google Scholar
• Thio CL, Seaberg EC, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–1926.
   PubMed Web of Science ®Google Scholar
• Winston J, Deray G, Hawkins T, Szczech L, Wyatt C, Young B. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis. 2008;47:1449–1457.
   PubMed Web of Science ®Google Scholar
• Jones R, Scott C, Nelson M, Levy J. Renal complications in HIV. Int J Clin Practice. 2007;61:991–998.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Asso-ciation of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585.
   PubMed Web of Science ®Google Scholar
• Moore RD, Gebo KA, Lucas GM, Keruly JC. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis. 2008;47:1102–1104.
   PubMed Web of Science ®Google Scholar
• Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infec-tion. AIDS. 2008;22:841–848.
   PubMed Web of Science ®Google Scholar
• Belloso WH, Orellana LC, Grinsztejn B, et al. Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites [published online ahead of print March 21,2010]. HIV Med.
   PubMed Web of Science ®Google Scholar
• De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers--are we being naive? J Infect Dis. 1997;175:237-246.
   Google Scholar
• Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med. 1996;125: 605–613.
   PubMed Web of Science ®Google Scholar
• Concorde Coordinating Committee. Concorde: MRC/ ANRS randomised double-blind controlled trial of immedi-ate and deferred zidovudine in symptom-free HIV infec-tion. Lancet. 1994;343:871–881.
   PubMed Web of Science ®Google Scholar
• The INSIGHT-ESPRIT Study Group and SILCAAT Scien-tific Committee. Interleukin-2 therapy in patients with HIV Infection. N Engl J Med. 2009;361:1548–1559.
   PubMed Web of Science ®Google Scholar
• Hughes MD. Initial treatment of HIV infection: randomized trials with clinical endpoints are still needed. J Infect Dis. 2006;194:542–544.
   PubMed Web of Science ®Google Scholar
• Lifson AR, INSIGHT Cause of Death Writing Group. Deter-mination of the underlying cause of death in three mul-ticenter international HIV clinical trials. HIV Clin Trials. 2008;9:177–185.
   PubMed Web of Science ®Google Scholar
• Lifson AR, Rhame FS, Belloso WH, et al. Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. HIV Clin Trials. 2006;7:125–141.
   PubMed Web of Science ®Google Scholar
• Green LA, Rhame FS, Price RW, et al. Experience with a cross-study endpoint review committee for AIDS clinical trials. AIDS. 1998;12:1983–1990.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21:1957–1963.
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, White HD, et al. Universal defini-tion of myocardial infarction. Circulation. 2007;116:2634–2653.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classifica-tion of diabetes mellitus. Diabetes Care. 2007;30(Suppl 1):S42–47.
   PubMedGoogle Scholar
• Wells PS, Anderson DR, Bormanis J, et al. Value of assess-ment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997;350:1795–1798.
   PubMed Web of Science ®Google Scholar
• The SMART/INSIGHT and D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;21:F17–24.
   Web of Science ®Google Scholar
• The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. New Engl J Med. 2007;356:1723–1735.
   PubMed Web of Science ®Google Scholar
• Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoff-man R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283–290.
   PubMed Web of Science ®Google Scholar
• Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS. 2007;21:1739–1745.
   PubMed Web of Science ®Google Scholar
• Kyriakides TC, Babiker A, Singer J, et al. An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Control Clin Trials. 2003;24:481–500.
   PubMedGoogle Scholar
• Kamin DS, Grinspoon SK. Cardiovascular disease in HIV-positive patients. AIDS. 2005;19: 641–652.
   PubMed Web of Science ®Google Scholar
• Murphy R, Costagliola D. Increased cardiovascular risk in HIV infection: drugs, virus and immunity. AIDS. 2008;22:1625–1627.
   PubMed Web of Science ®Google Scholar
• Periard D, Cavassini M, Taffe P, et al. HIV prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis. 2008;46:761–767.
   PubMed Web of Science ®Google Scholar
• Fultz SL, McGinnis KA, Skanderson M, Ragni MV, Justice AC. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med. 2004;116:420–423.
   PubMed Web of Science ®Google Scholar
• Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin lnfec Dis. 2009;49: 1119–1127.
   PubMed Web of Science ®Google Scholar
• Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TRH. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health. In press.
   Web of Science ®Google Scholar
• Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Man-agement of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977–2016.
   Google Scholar
• Tovey C, Wyatt S. Diagnosis, investigation and manage-ment of deep vein thrombosis. Br Med J. 2003;326:1180–1184.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Snow V, Barry P, et al. Current diagnosis of venous thromboembolism in primary care: a clinical prac-tice guideline from the American Academy of Family Phy-sicians and the American College of Physicians. Ann Fam Med. 2007;5:57–62.
   PubMed Web of Science ®Google Scholar